                               SEQUENCE LISTING

<110> THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
 
<120> STRUCTURE-BASED PEPTIDE INHIBITORS THAT TARGET THE TAU VQIINK 
      FIBRILLIZATION SEGMENT

<130> 30435.331-WO-U1

<140> PCT/US2018/022742
<141> 2018-03-15

<150> 62/471,831
<151> 2017-03-15

<160> 33    

<170> PatentIn version 3.5

<210> 1
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 1
Lys Val Gln Ile Ile Asn Lys Lys Leu Asp 
1               5                   10  


<210> 2
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 2
Asp Val Gln Met Ile Asn Lys Lys Arg Lys 
1               5                   10  


<210> 3
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 3
Asp Val Gln Trp Ile Asn Lys Lys Arg Lys 
1               5                   10  


<210> 4
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 4
Asp Val Gln Arg Ile Asn Lys Lys Arg Lys 
1               5                   10  


<210> 5
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 5
Asp Val Trp Met Ile Asn Lys Lys Arg Lys 
1               5                   10  


<210> 6
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 6
Asp Val Trp Trp Ile Asn Lys Lys Arg Lys 
1               5                   10  


<210> 7
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 7
Asp Val Trp Met Trp Asn Lys Lys Arg Lys 
1               5                   10  


<210> 8
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 8
Asp Val Trp Trp Trp Asn Lys Lys Arg Lys 
1               5                   10  


<210> 9
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 9
Val Gln Ile Val Tyr Lys 
1               5       


<210> 10
<211> 440
<212> PRT
<213> Homo sapiens

<400> 10
Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly 
1               5                   10                  15      


Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His 
            20                  25                  30          


Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu 
        35                  40                  45              


Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser 
    50                  55                  60                  


Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val 
65                  70                  75                  80  


Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu 
                85                  90                  95      


Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro 
            100                 105                 110         


Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Ala Arg Met Val 
        115                 120                 125             


Ser Lys Ser Lys Asp Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Gly 
    130                 135                 140                 


Ala Asp Gly Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro 
145                 150                 155                 160 


Gly Gln Lys Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro 
                165                 170                 175     


Pro Ala Pro Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly 
            180                 185                 190         


Asp Arg Ser Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser 
        195                 200                 205             


Arg Ser Arg Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys 
    210                 215                 220                 


Lys Val Ala Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys 
225                 230                 235                 240 


Ser Arg Leu Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val 
                245                 250                 255     


Lys Ser Lys Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly 
            260                 265                 270         


Gly Lys Val Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln 
        275                 280                 285             


Ser Lys Cys Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Gly 
    290                 295                 300                 


Ser Val Gln Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser 
305                 310                 315                 320 


Lys Cys Gly Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln 
                325                 330                 335     


Val Glu Val Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser 
            340                 345                 350         


Lys Ile Gly Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn 
        355                 360                 365             


Lys Lys Ile Glu Thr His Lys Leu Thr Phe Arg Glu Asn Ala Lys Ala 
    370                 375                 380                 


Lys Thr Asp His Gly Ala Glu Ile Val Tyr Lys Ser Pro Val Val Ser 
385                 390                 395                 400 


Gly Asp Thr Ser Pro Arg His Leu Ser Asn Val Ser Ser Thr Gly Ser 
                405                 410                 415     


Ile Asp Met Val Asp Ser Pro Gln Leu Ala Thr Leu Ala Asp Glu Val 
            420                 425                 430         


Ser Ala Ser Leu Ala Lys Gln Gly 
        435                 440 


<210> 11
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 11
Val Gln Ile Ile Asn Lys 
1               5       


<210> 12

<400> 12
000


<210> 13
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MISC_FEATURE
<222> (1)..(16) 
<223> This sequence may encompass 5-16 residues

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 13
Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg 
1               5                   10                  15      


<210> 14
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 14
Arg Gly Gly Arg Leu Ser Tyr Ser Arg Arg Arg Phe Ser Thr Ser Thr 
1               5                   10                  15      


Gly Arg 
        


<210> 15
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 15
Arg Arg Leu Ser Tyr Ser Arg Arg Arg Phe 
1               5                   10  


<210> 16
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 16
Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 
1               5                   10                  15      


<210> 17
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 17
Arg Gln Ile Arg Ile Trp Phe Gln Asn Arg Arg Met Arg Trp Arg Arg 
1               5                   10                  15      


<210> 18
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 18
Lys Gln Ile Lys Ile Trp Phe Gln Asn Lys Lys Met Lys Trp Lys Lys 
1               5                   10                  15      


<210> 19
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 19
Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Trp Gln 
1               5                   10              


<210> 20
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 20
Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Pro Gln 
1               5                   10              


<210> 21
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 21
Gly Arg Arg Arg Arg Arg Arg Arg Arg Arg Pro Pro Gln 
1               5                   10              


<210> 22
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 22
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1               5                   10      


<210> 23
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MOD_RES
<222> (1)..(13) 
<223> D-amino acid

<400> 23
Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Pro Gln 
1               5                   10              


<210> 24
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 24
Lys Met Thr Arg Ala Gln Arg Arg Ala Ala Ala Arg Arg Asn Arg Trp 
1               5                   10                  15      


Thr Ala Arg 
            


<210> 25
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 25
Lys Val Pro Asp 
1               


<210> 26
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 26
Leu Asp Leu Ser Asn 
1               5   


<210> 27
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MISC_FEATURE
<222> (1)..(16) 
<223> This sequence may encompass 5-16 residues

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 27
Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
1               5                   10                  15      


<210> 28
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide


<220>
<221> MISC_FEATURE
<222> (1)..(16) 
<223> This sequence may encompass 1-16 residues

<220> 
<223> See specification as filed for detailed description of
      substitutions and preferred embodiments

<400> 28
Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg 
1               5                   10                  15      


<210> 29
<211> 31
<212> PRT
<213> Homo sapiens

<400> 29
Lys Val Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser 
1               5                   10                  15      


Lys Cys Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Gly 
            20                  25                  30      


<210> 30
<211> 31
<212> PRT
<213> Homo sapiens

<400> 30
Ser Val Gln Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser 
1               5                   10                  15      


Lys Cys Gly Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly 
            20                  25                  30      


<210> 31
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 31
Lys Lys Leu Asp 
1               


<210> 32
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 32
Val Gln Ile Tyr Val Lys 
1               5       


<210> 33
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      peptide

<400> 33
Val Gln Ile Val Ile Tyr Lys 
1               5           


